This is a trial of TTI-621 in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.
| SparkCures ID | 896 |
|---|---|
| Trial Phase | Phase 1 |
| Enrollment | 250 Patients |
| Treatments | |
| Tags | |
| Trial Sponsors |
|
| NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Please visit the ClinicalTrials.gov page for historical site information.
View Centers